^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

1263 - Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pathway inhibition strategy

Published date:
03/10/2021
Excerpt:
Similarly, in the H358 KRAS G12C mt NSCLC model, triple combination of VS-6766, sotorasib and a FAK inhibitor induced >35% tumor regression in 10/10 mice following 21 days of treatment.